Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Difelikefalin Acetate Patent Expiration

Difelikefalin Acetate is Used for managing moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. It was first introduced by Cara Therapeutics Inc in its drug Korsuva on Aug 23, 2021.


Difelikefalin Acetate Patents

Given below is the list of patents protecting Difelikefalin Acetate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Korsuva US10017536 Synthetic peptide amides and dimers thereof Nov 12, 2027 Cara Therap
Korsuva US10138270 Synthetic peptide amides Nov 12, 2027 Cara Therap
Korsuva US10793596 Synthetic peptide amides Nov 12, 2027 Cara Therap
Korsuva US7402564 Synthetic peptide amides Nov 12, 2027 Cara Therap
Korsuva US7713937 Synthetic peptide amides and dimeric forms thereof Nov 12, 2027 Cara Therap
Korsuva US7727963 Synthetic peptide amides Nov 12, 2027 Cara Therap
Korsuva US8217007 Synthetic peptide amides Nov 12, 2027 Cara Therap
Korsuva US8236766 Uses of synthetic peptide amides Nov 12, 2027 Cara Therap
Korsuva US8486894 Synthetic peptide amides and dimeric forms thereof Nov 12, 2027 Cara Therap
Korsuva US8536131 Synthetic peptide amides and dimers thereof Nov 12, 2027 Cara Therap
Korsuva US9334305 Synthetic peptide amides and dimers thereof Nov 12, 2027 Cara Therap
Korsuva US9359399 Synthetic peptide amides Nov 12, 2027 Cara Therap


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳